Reliability of Insulin by Jet Injection

Overview

Using a specific jet injector for the administration of a rapid-acting insulin analogue has been shown to advance the absorption of insulin from the subcutaneous area into the bloodstream by 40-50%, when compared to conventional injection by insulin pens. The reproducibility of the jet stream method has not been previously determined in vivo. It is also unknown how the efficacy of injecting regular insulin by jet stream compares to that of rapid-acting analogues injected by conventional pen. Objectives: 1. To compare the pharmacologic reproducibility of the rapid-acting insulin analogue aspart (Novorapid®) injected by jet-injection to that of the same insulin injected with a conventional pen. 2. To compare pharmacokinetic and -dynamic profile of regular insulin injected by jet injection to that of aspart insulin injected by conventional pen. Study design: Double-blind double-dummy randomized controlled parallel/cross-over

1. Introduction Insulin administration by a jet injector is a needle-free alternative to conventional administration of insulin by insulin pens or syringes. Jet injectors deliver insulin at a high velocity (typically \>100m/s) across the skin in the subcutaneous tissue and dispense the insulin over a larger area than insulin injected with a syringe. This significantly accelerates absorption of rapid-acting insulin from the subcutaneous area into the systemic circulation. Reproducibility of the insulin effect is an essential, but easily overlooked, issue for a product that needs to be administered so frequently in daily practice. When identical doses of aspart insulin were injected by a common syringe on two different days separated by at least a week, the intra-individual and inter-individual variability of various pharmacokinetic and -dynamic parameters was found to vary between 11-21% and 18-36%, respectively. Reproducibility has not been investigated when insulin was administered by jet injectors. The investigators previous studies indicated smaller between-subjects variability in insulin absorption after injection by this jet injector than after injection by conventional pen, providing some evidence that reproducibility is at least comparable, but potentially even better when using a jet injector. The aim of the present research proposal is to compare the variability of the metabolic effect of insulin aspart when administered by jet injection to that when injected by conventional insulin pen, under controlled experimental conditions. An additional aim is to investigate the pharmacokinetic and -dynamic comparability between regular soluble insulin injected by the jet stream device with aspart insulin administered by conventional pen. The reason the investigators wanted to investigate the comparability is that rapid-acting insulin analogs are not worldwide available and very costly compared to regular insulin. If you could achieve the same pharmacological benefits as rapid acting insulin with a less costly type of insulin, this would be of great benefit for patients with diabetes in less developed countries. 2. Hypotheses The variability of the metabolic effect of insulin administered subcutaneously by jet injection is similar to or better than that of insulin administered by a conventional insulin pen. The investigators also hypothesize that the metabolic effect of soluble insulin administered by jet injection is similar to that of insulin aspart administered by conventional insulin pen. 3. Study Population For this study, a total of 30 healthy volunteers will be recruited. Subjects are potentially eligible when they are between 18 and 50 years of age and in good clinical condition. Additional participants will be recruited in case of drop-out. 4. Investigational medicinal products Main study: Insulin aspart (Novorapid® Penfill 100 units/ml, 3 ml ampoule): rapid-acting analogue of human insulin. Sub-study: Regular Human Insulin (Humulin® Penfill 100 units/ml, 3ml ampoule): human regular insulin. 5. Summary of known and potential risks and benefits Novorapid® insulin is indicated for the treatment of diabetes mellitus in adults, adolescents and children above the age of 2 years. The study comprises a risk of hypoglycemia. However, the risk of hypoglycaemia during the experiment is negligible, since glucose is measured at 5-10 minute intervals and additional glucose will be administered should glucose levels tend to drop below 4.8 mmol/l. Intravenous glucose 20% may cause local irritation and occasionally phlebitis. 6. Methods 6.1 Randomisation The study will have a randomised controlled parallel design. Randomisation will be done by a computer program with the use of blocks of two subjects, to randomize which of the two devices will contain insulin and which placebo solution. This will ensure that equal number of subjects will have the experiment with the investigational product (InsujetTM pen) or with the control device (Novopen® IV insulin pen). To ensure blinding, both pen devices will be prepared by a nurse who is not otherwise involved in conducting the experiments. There is no indication for prematurely breaking the randomisation code, as subjects will receive the same amount of insulin with one of the two devices in each experiment, with frequent glucose-monitoring to prevent hypoglycemia. 6.2 Study procedures Potentially eligible study participants will be recruited using websites or by using the RUMC social media. Should this be insufficient, advertisements in local newspapers will be placed. Eligibility will be determined at the screening visit after a medical interview and physical examination. Experimental procedures All participants will be examined on two occasions, within 1 week, with one of the two devices containing insulin and the other device as a placebo device. Patients will be instructed to consume a low-glycemic index meal the evening before experiments and remain in fasting condition from 20:00 hours onwards. On the first and second experimental day, participants will be admitted to the research unit at 08.00 hours in fasting condition and having abstained from smoking, alcohol use and caffeine use for at least 24 hours. A catheter will be inserted in retrograde fashion in a dorsal hand vein for frequent blood sampling, whereby the hand will be placed inside a heated box (air temperature, \~55°C) to arterialize venous blood. Another catheter will be inserted in the antecubital vein of the other arm, which will be kept patent by saline drip, and which will be used for administration of 20% glucose. After cannulations, blood will be taken for direct measurement of plasma glucose and stored for later measurement of plasma insulin levels. Thereafter, an independent research nurse will administer insulin at a dose of 0.2 units per kg body weight subcutaneously at the abdominal site, with either the jet injector (InsujetTM) or the conventional pen (Novopen® IV). The device not used for insulin administration will be prepared by the research nurse as well. However, this device is empty although to the patient it will look and feel the same way as the pens filled with insulin. The insulin injection and the simulated injection will be given simultaneously. After injection, the administration site will be covered by the research nurse with a bandage to prevent that the investigator and patient will be able to see whether there has remained some insulin on the skin or not. The investigators as well as the participants will be blinded to which pen contains the insulin and which pen was the placebo device. Subsequently, a 6-hour normoglycemic glucose clamp will be employed, as described previously. To this end, glucose 20% will be administered intravenously at a sufficient rate to maintain normoglycemia, based on plasma glucose levels measured at 5-minute intervals during the first 3 hours and at 10-minute intervals during the remainder of the experiment. Also, blood will be drawn and stored at -80°C every 5 minutes during the first hour after insulin injection and every 15 minutes during the hour thereafter for later determination of plasma insulin and C-peptide levels. During the last four hours, insulin will be measured with 30 minutes intervals. Six hours after the insulin injection, the experiment will be terminated and the patients will be given a meal. The total duration of the study day, including preparation and recovery time, will be 7 hours. Participants will be asked separately to return to the research unit a third time for a similar 6-hour normoglycemic glucose clamp. On this occasion, the insulin aspart will be replaced by regular soluble insulin. The insulin will be administered by the jet injector. Pharmacokinetic and -dynamic data obtained from this experiment will be compared with data obtained after injection of aspart insulin by conventional pen both in this study and in a previous investigation. The investigators will also ask the subject on both experimental days, within 30 minutes after insulin injection, to point out on a numeric rating scale from 0 to 10 the amount of discomfort or pain and the ease of use experienced with the two administration methods. After the second experiment day, patients will be asked which of the two devices they would prefer for insulin injection, should they have a choice. Withdrawal of study subjects Subjects can leave the study at any time for any reason if they wish to do so without any consequences. The investigator can decide to withdraw a subject from the study in case of a severe adverse event or another condition requiring immediate medical care. Appropriate follow up and treatment of withdrawn subjects will be assured. Every subject that withdraws from the study will be replaced with an additional study participant. Premature termination of the study The study will be terminated prematurely when unexpected serious adverse events are experienced which endanger other subjects. If the trial is prematurely terminated the investigator will promptly inform the trial subjects, the METC and competent authority. A detailed written explanation of the termination will be provided. Appropriate follow up and treatment of trial subjects will be assured. 7. Safety reporting The investigator will inform the subjects and the reviewing accredited METC if anything occurs, on the basis of which it appears that the disadvantages of participation may be significantly greater than was foreseen in the research proposal. The study will be suspended pending further review by the accredited METC, except insofar as suspension would jeopardise the subjects' health. The investigator will take care that all subjects are kept informed. All (serious) adverse events reported spontaneously by the subject or observed by the investigator or his staff will be recorded and reported at the METC. 8. Statistical analysis Descriptive parameters will be presented as mean ± standard error of the mean. Unpaired T-tests will be performed to compare all main and secondary study endpoints as well as most ease of use and safety endpoints. A Chi2 test will be used to compare the number of patients experiencing post injection hypoglycaemia with the two injection devices. A P-value of \< 0.05 will be considered as statistically significant. All statistical analyses will be performed using SPSS 20.0 or higher. 9. Administrative aspects, monitoring and publication The investigator will preserve confidentiality of all subjects taking part in the study, in accordance with GCP and local regulations. The investigator must ensure that the subjects anonymity is maintained. Al data and material from one individual subject will be coded by an unique identification code. The key to the code is maintained by the investigator and research nurses. The validated data management system Castor will be used for data handling, according to GCP. Data will be stored for 15 years. Human material will be stored for 10 years. Source document and database verification will be performed by an independent monitor, according to a predefined monitoring plan. There will be minimal monitoring, once per year, as the study is judged to cause only marginal potential risk to the participants. 10. Public disclosure and publication policy This study has been made possible by an unrestricted grant from European Pharma Group (EPG), division Needle Free Insulin Products, the manufacturer of the InsujetTM jet-injector. EPG was not involved in the study design or writing of the protocol and will also not be involved in conducting the study, analysis of the data, presentation of the results, writing of the manuscript and the decision to submit for publication.